Subgroups, Study Design, and the Impact of the Biosimilar Extension Rule

How and when to accommodate a subgroup in your biosimilar study

Read more

This article analyzes the considerations regarding the optimal design of a pivotal Phase III biosimilar study.


Chief Medical and Scientific Officer

Want to learn more about Worldwide Clinical Trials?